Author
Listed:
- Jürgen Wasem
(University of Duisburg-Essen)
- Yanic Heer
(PricewaterhouseCoopers (PwC))
- Eleni Karamasioti
(PricewaterhouseCoopers (PwC))
- Erwan Muros-Le Rouzic
(F. Hoffmann-La Roche Ltd.)
- Giuseppe Marcelli
(F. Hoffmann-La Roche Ltd.)
- Danilo Maio
(F. Hoffmann-La Roche Ltd.)
- Stefan Braune
(NeuroTransData GmbH)
- Gisela Kobelt
(EHE International
European Health Economics)
- Paul Dillon
(F. Hoffmann-La Roche Ltd.)
Abstract
Background and Objective Understanding the socioeconomic burden of multiple sclerosis (MS) is essential to inform policymakers and payers. Real-world studies have associated increasing costs and worsening quality of life (QoL) with disability progression. This study aims to further evaluate the impact of cognition, fatigue, upper and lower limb function (ULF, LLF) impairments, and disease progression per Expanded Disability Status Scale (EDSS) level, on costs and QoL. Methods This was a cross-sectional cohort study including 20,988 patients from the German NeuroTransData MS registry from 2009 to 2019. QoL analyses were based on EQ-5D-5L. Cost analyses included indirect/direct medical and non-medical costs. Eight subgroups, ranging from 439 to 1812 patients were created based on presence of measures for disease progression (EDSS), cognition (Symbol Digit Modalities Test [SDMT]), fatigue (Modified Fatigue Impact 5-Item Scale [MFIS-5]), ULF (Nine-Hole Peg Test [9HPT]), and LLF (Timed 25-Foot Walk [T25FW]). Multivariable linear regression assessed the independent effect of each test’s score on QoL and costs, while adjusting for EDSS and 12 other confounders. Results Lower QoL was associated with decreasing cognition (p
Suggested Citation
Jürgen Wasem & Yanic Heer & Eleni Karamasioti & Erwan Muros-Le Rouzic & Giuseppe Marcelli & Danilo Maio & Stefan Braune & Gisela Kobelt & Paul Dillon, 2024.
"Cost and Quality of Life of Disability Progression in Multiple Sclerosis Beyond EDSS: Impact of Cognition, Fatigue, and Limb Impairment,"
PharmacoEconomics - Open, Springer, vol. 8(5), pages 665-678, September.
Handle:
RePEc:spr:pharmo:v:8:y:2024:i:5:d:10.1007_s41669-024-00501-x
DOI: 10.1007/s41669-024-00501-x
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharmo:v:8:y:2024:i:5:d:10.1007_s41669-024-00501-x. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.